ApoCell, Inc. Awarded $2.9 Million from SAIC-Frederick, Inc. to Deliver a New Platform for Detection and Molecular Analysis of Circulating Tumor Cells (CTCs) to the National Cancer Institute’s Pharmacodynamics Program

HOUSTON--(BUSINESS WIRE)--ApoCell, Inc. announced the award of a $2.9 million contract from SAIC-Frederick Inc. (SAIC-F), in support of the National Cancer Institute, for the development and delivery of 12 alpha prototype units of the ApoCell DEP-FFF circulating tumor cell (CTC) detection system, called ApoStream™. The project, funded by the American Recovery and Reinvestment Act (ARRA), is for the delivery of technology for CTC capture and analysis to determine the effects of targeted cancer therapies.